• 1
    Diepolder HM, Jung MC, Keller E, Schraut W, Gerlach JT, Gruner N, et al. A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin Exp Immunol 1998; 113: 244251.
  • 2
    Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999; 53: 459469.
  • 3
    Donaldson PT, Norris S. Immunogenetics in PSC. Best Pract Res Clin Gastroenterol 2001; 15: 611627.
  • 4
    Cullen S, Chapman R. Primary sclerosing cholangitis. Autoimmun Rev 2003; 2: 305312.
  • 5
    Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968974.
  • 6
    Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352: 595600.
  • 7
    Kuzushita N, Hayashi N, Katayama K, Hiramatsu N, Yasumaru M, Murata H, et al. Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels. J Med Virol 1996; 48: 17.
  • 8
    Chen Y, Winchester R, Korber B, Gagliano J, Bryson Y, Hutto C, et al. Influence of HLA alleles on the rate of progression of vertically transmitted HIV infection in children: Association of several HLA-DR13 alleles with long-term survivorship and the potential association of HLA-A*2301 with rapid progression to AIDS. Long-term survivor study. Hum Immunol 1997; 55: 154162.
  • 9
    Thursz MR, Kwiatkowski D, Allsopp CEM, Greenwood BM, Thomas HC, Hill AVS. Association between a MHC class II alle and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995; 332: 10651069.
  • 10
    Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, et al. HLA-DRB1*1301 and 1302 protect against chronic hepatitis B. J Hepatol 1997; 26: 503507.
  • 11
    Ahn SH, Han KH, Park JY, Lee CK, Kang SW, Chon CY, et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology 2000; 31: 13711373.
  • 12
    Cao T, Desombere I, Vanlandschoot PV, Sallberg M, Leroux-Roels G. Characterization of HLA DR13-restricted CD4(+) T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B. J Gen Virol 2002; 83: 30233033.
  • 13
    Hastings AE, Hurley CK, Robinson ED, Salerno K, Hernandez E, Richert JR. Molecular interactions between transfected human TCR, immunodominant myelin basic protein peptid 152-165, and HLA-DR13. J Immunol 1996; 157: 34603471.
  • 14
    Vierling JM. Aetiopathogenesis of primary sclerosing cholangitis. In: MannsPCR, StieihlA, WiesnerR, eds. Primary Sclerosing Cholangitis. London: Kluwer Academic Publishers; 1998: 9.
  • 15
    Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995; 22: 451457.
  • 16
    Oertel M, Berr F, Schroder S, Schwarz R, Tannapfel A, Wenzke M, et al. Acute rejection of hepatic allografts from HLA-DR13(allele DRB1*1301)-positive donors. Liver Transpl 2000; 6: 728733.